G Verstappen, X Bertels, R O Al-Lehebi, B M Alim, N H Alotaibi, S Alsaleh, V Backer, M Bernal-Sprekelsen, B S Bleier, Y Chan, D M Conti, M E Cornet, E de Corso, P Gevaert, J Hagenmann, J Han, C H Hopkins, M Jeseňák, E Khaleva, S Lau, S E Lee, V J Lund, A T Peters, C Pipolo, K F Rabe, G Scadding, S Schneider, B A Senior, P K Smith, M E Wechsler, W J Fokkens, P W Hellings
{"title":"Pocket guide Biologics in upper and lower airway diseases 2026 by EUFOREA.","authors":"G Verstappen, X Bertels, R O Al-Lehebi, B M Alim, N H Alotaibi, S Alsaleh, V Backer, M Bernal-Sprekelsen, B S Bleier, Y Chan, D M Conti, M E Cornet, E de Corso, P Gevaert, J Hagenmann, J Han, C H Hopkins, M Jeseňák, E Khaleva, S Lau, S E Lee, V J Lund, A T Peters, C Pipolo, K F Rabe, G Scadding, S Schneider, B A Senior, P K Smith, M E Wechsler, W J Fokkens, P W Hellings","doi":"10.4193/Rhin26.419","DOIUrl":null,"url":null,"abstract":"<p><p>Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice (1). Real-world studies confirm their effectiveness beyond controlled clinical trial settings and highlight biologics as a major therapeutic advance for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and eosinophilic chronic obstructive pulmonary disease (COPD) (2-4). Biologics have been shown to significantly improve disease control and potentially enable the achievement of new treatment goals, including clinical and complete remission (5).</p>","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rhinology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4193/Rhin26.419","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Over the past decade, biologic therapies targeting key inflammatory pathways have fundamentally transformed the treatment landscape for patients with chronic inflammatory airway diseases. These therapies are now widely approved worldwide and increasingly implemented in routine clinical practice (1). Real-world studies confirm their effectiveness beyond controlled clinical trial settings and highlight biologics as a major therapeutic advance for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and eosinophilic chronic obstructive pulmonary disease (COPD) (2-4). Biologics have been shown to significantly improve disease control and potentially enable the achievement of new treatment goals, including clinical and complete remission (5).
期刊介绍：
Rhinology serves as the official Journal of the International Rhinologic Society and is recognized as one of the journals of the European Rhinologic Society. It offers a prominent platform for disseminating rhinologic research, reviews, position papers, task force reports, and guidelines to an international scientific audience. The journal also boasts the prestigious European Position Paper in Rhinosinusitis (EPOS), a highly influential publication first released in 2005 and subsequently updated in 2007, 2012, and most recently in 2020.
Employing a double-blind peer review system, Rhinology welcomes original articles, review articles, and letters to the editor.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
